Long-Term Effect of Colestimide on Glycemic Control in Patients with Type 2 Diabetes with Elevated Low-Density Lipoprotein Cholesterol Levels

Takebayashi, Kohzo; Suetsugu, Mariko; Aso, Yoshimasa; Inukai, Toshihiko

doi:https://doi.org/10.3814/2010/973413

SRX Medicine

On this page

Abstract References Copyright Related Articles

Clinical Study | Open Access

Volume 2010 | Article ID 973413 | https://doi.org/10.3814/2010/973413

Long-Term Effect of Colestimide on Glycemic Control in Patients with Type 2 Diabetes with Elevated Low-Density Lipoprotein Cholesterol Levels

Kohzo Takebayashi,¹Mariko Suetsugu,¹Yoshimasa Aso,¹and Toshihiko Inukai¹

Received12 Oct 2009

Revised24 Oct 2009

Accepted25 Oct 2009

Published13 Jan 2010

Abstract

Objective. Bile acid sequestrants (BASs) have been shown to improve both low-density lipoprotein-(LDL-) cholesterol and hemoglobin (Hb) A1c levels in patients with type 2 diabetes with elevated LDL levels. However, the longitudinal effect on glycemic control in these patients has not been fully examined. In the current study, the effect of colestimide (a BAS used in Japan, called also as colestilan) over a mean period of 18 months was investigated in patients with type 2 diabetes with elevated LDL levels. Methods. The study was performed prospectively in 34 patients with type 2 diabetes with elevated LDL levels who started colestimide (3.0 g a day) between April 2007 and March 2008. Results. HbA1c was significantly decreased after 3 months of colestimide therapy and at the end point of treatment (a mean period of 18 months) compared with baseline values (8.1%±1.1% at baseline, 7.1%±0.7% at 3 months, and 7.2%±0.9% at the end point; both P<.0001 versus baseline; P>.05, 3 months versus end point). Colestimide also significantly reduced LDL-C at 3 months and at the end point (both P<.0001 versus baseline; P>.05, 3 months versus end point). However, fasting plasma glucose, triglycerides, systolic and diastolic blood pressure, and body weight did not differ significantly after 3 months and at the end point compared with the respective baseline values. Conclusion. Colestimide significantly decreased HbA1c over a relatively long-term period in patients with type 2 diabetes with elevated LDL levels.

References

A. Garg and S. M. Grundy, “Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial,” Annals of Internal Medicine, vol. 121, no. 6, pp. 416–422, 1994.
View at: Google Scholar
F. J. Zieve, M. F. Kalin, S. L. Schwartz, M. R. Jones, and W. L. Bailey, “Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes,” Clinical Therapeutics, vol. 29, no. 1, pp. 74–83, 2007.
View at: Publisher Site | Google Scholar
H. E. Bays, R. B. Goldberg, K. E. Truitt, and M. R. Jones, “Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects,” Archives of Internal Medicine, vol. 168, no. 18, pp. 1975–1983, 2008.
View at: Publisher Site | Google Scholar
R. B. Goldberg, V. A. Fonseca, K. E. Truitt, and M. R. Jones, “Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy,” Archives of Internal Medicine, vol. 168, no. 14, pp. 1531–1540, 2008.
View at: Publisher Site | Google Scholar
V. A. Fonseca, J. Rosenstock, A. C. Wang, K. E. Truitt, and M. R. Jones, “Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy,” Diabetes Care, vol. 31, no. 8, pp. 1479–1484, 2008.
View at: Publisher Site | Google Scholar
T. Yamakawa, T. Takano, H. Utsunomiya, K. Kadonosono, and A. Okamura, “Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia,” Endocrine Journal, vol. 54, no. 1, pp. 53–58, 2007.
View at: Publisher Site | Google Scholar
K. Takebayashi, M. Suetsugu, S. Matsumoto, Y. Aso, and T. Inukai, “Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia,” Southern Medical Journal, vol. 102, no. 4, pp. 361–368, 2009.
View at: Publisher Site | Google Scholar
K. Takebayashi, Y. Aso, and T. Inukai, “Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes,” Metabolism, vol. 53, no. 6, pp. 693–699, 2004.
View at: Publisher Site | Google Scholar
Japan Diabetes Society, Treatment Guide for Diabetes, Bunkodo, Tokyo, Japan, 2007.
H. E. Bays and R. B. Goldberg, “The ‘forgotten’ bile acid sequestrants: is now a good time to remember?” American Journal of Therapeutics, vol. 14, no. 6, pp. 567–580, 2007.
View at: Publisher Site | Google Scholar
H. M. Colhoun, D. J. Betteridge, P. N. Durrington et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial,” The Lancet, vol. 364, no. 9435, pp. 685–696, 2004.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2010 Kohzo Takebayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

215

Downloads

0

Citations